Cargando…
Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
Autores principales: | Kinoshita, Taku, Shinoda, Masahiro, Nishizaki, Yasuhiro, Shiraki, Katsuya, Hirai, Yuji, Kichikawa, Yoshiko, Tsushima, Kenji, Shinkai, Masaharu, Komura, Naoyuki, Yoshida, Kazuo, Kido, Yasutoshi, Kakeya, Hiroshi, Uemura, Naoto, Kadota, Junichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733017/ https://www.ncbi.nlm.nih.gov/pubmed/36482439 http://dx.doi.org/10.1186/s12916-022-02695-5 |
Ejemplares similares
-
A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
por: Kinoshita, Taku, et al.
Publicado: (2022) -
Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016) -
Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020) -
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
por: Gunst, Jesper D., et al.
Publicado: (2021) -
A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats
por: Iwata, Yasunobu, et al.
Publicado: (2023)